Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 210858
Company: IBSA
Company: IBSA
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| VYBRIQUE | SILDENAFIL CITRATE | EQ 25MG BASE | FILM;ORAL | Prescription | None | Yes | No |
| VYBRIQUE | SILDENAFIL CITRATE | EQ 50MG BASE | FILM;ORAL | Prescription | None | Yes | No |
| VYBRIQUE | SILDENAFIL CITRATE | EQ 75MG BASE | FILM;ORAL | Prescription | None | Yes | No |
| VYBRIQUE | SILDENAFIL CITRATE | EQ 100MG BASE | FILM;ORAL | Prescription | None | Yes | Yes |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 12/16/2025 | ORIG-1 | Approval | Type 3 - New Dosage Form | STANDARD |
Label (PDF)
Letter (PDF) |
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210858s000lbl.pdf httpS://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/210858Orig1s000ltr.pdf |
| Action Date | Submission | Supplement Categories or Approval Type | Letters, Reviews, Labels, Patient Package Insert |
Note | Url |
|---|---|---|---|---|---|
| 12/16/2025 | ORIG-1 | Approval | Label (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/210858s000lbl.pdf |